Join experts from the field of cancer research to hear their thoughts on what the future of the discipline holds

Ichnos is currently evaluating two T cell engagers in clinical trials that are based on the BEAT® 1.0 bispecific antibody (bsAb) platform (Bispecific Engagement by Antibodies based on the T-cell receptor). To further improve the platform and in particular increase the ease of scalability, the Ichnos’ BEAT® 2.0 next generation bsAb platform addresses potential light chain mispairing with common light chain (cLc) technology. We have generated a range of multispecific antibodies having the potential to tackle more complex molecular and cellular mechanisms whilst maintaining favorable developability profiles.